Glycine, N-[(1-methylethoxy)acetyl]- | 33445-08-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Glycine, N-[(1-methylethoxy)acetyl]-
• 英文别名: 2-[(2-propan-2-yloxyacetyl)amino]acetic acid
• CAS: 33445-08-8
• 化学式: C₇H₁₃NO₄
• 分子量: 175.18
• InChiKey: QKRNJVGIXIVEQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Non-nucleoside Reverse Transcriptase Inhibitors
  申请人：DeROY Patrick

  公开号：US20090143370A1

  公开（公告）日：2009-06-04

  Compounds of formula (I): wherein Ar, X, R 1 , R 2 , R 3 and R 4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.
• US8198458B2
  申请人：——

  公开号：US8198458B2

  公开（公告）日：2012-06-12
• [EN] COMPOUNDS AND COMPOSITIONS FOR EYE TREATMENTS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR TRAITEMENTS OCULAIRES
  申请人：AVEDRO INC

  公开号：WO2020117974A1

  公开（公告）日：2020-06-11

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that that generates cross-linking in the cornea in response to exposure to an electromagnetic irradiation. This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which in which abnormal shaping of the cornea (e.g., thinning of the cornea, e.g., bilateral thinning of the cornea, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or steepening (e.g., bulging) of the cornea) contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) corneal ectatic disorders; (ii) vision conditions; and (iii) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include keratoconus, keratoglobus, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Terrien's marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia.